Active Ingredient(s): Neratinib Maleate
FDA Approved: * July 17, 2017
Pharm Company: * PUMA BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Nerlynx Overview

Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer.[2][3] The most common side effect is diarrhea, which affects nearly all patients.[3] Other common side effects include nausea (feeling sick), vomiting, tiredness, belly pain, rash, decreased appetite, stomatitis (sore, inflamed mouth), and muscle spasms.[3] Contents 1 Medical uses 2 ...

Read more Nerlynx Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Nerlynx Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Neratinib Maleate
  • Tablet: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Nerlynx: (1 result)

Sorted by National Drug Code
  • 70437-240 Nerlynx 48.31 mg Oral Tablet by Puma Biotechnology, Inc.

Other drugs which contain Neratinib Maleate or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 12 May 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA